Publication | Closed Access
Immunotherapy with interleukin-2 after hematopoietic cell transplantation for hematologic malignancy.
15
Citations
0
References
2000
Year
These studies will help define the optimal dose and schedule of IL-2 and its role in augmenting therapeutic immune-mediated autologous responses.